Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.090
+0.180 (6.19%)
At close: Aug 13, 2025, 4:00 PM
3.010
-0.080 (-2.59%)
Pre-market: Aug 14, 2025, 8:41 AM EDT
Rocket Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Rocket Pharmaceuticals stock ranges from a low of $2.50 to a high of $44. The average analyst price target of $12.88 forecasts a 316.83% increase in the stock price over the next year.
Price Target: $12.88 (+316.83%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Rocket Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 4 | 4 |
| Hold | 1 | 1 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +255.99% | Aug 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +158.90% | Aug 8, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $11 → $10 | Strong Buy | Maintains | $11 → $10 | +223.62% | Jul 25, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Hold Downgrades $9 → $4 | Strong Buy → Hold | Downgrades | $9 → $4 | +29.45% | Jul 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 → $12 | Strong Buy | Maintains | $17 → $12 | +288.35% | Jul 24, 2025 |
Financial Forecast
Revenue This Year
11.08M
Revenue Next Year
76.63M
from 11.08M
Increased by 591.46%
EPS This Year
-2.26
from -2.73
EPS Next Year
-1.81
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 150.2M | 321.3M | 273.0M | ||
| Avg | 11.1M | 76.6M | 79.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,798.8% | 256.3% | ||
| Avg | - | 591.5% | 3.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.11 | -1.04 | 1.85 | ||
| Avg | -2.26 | -1.81 | -1.16 | ||
| Low | -2.53 | -2.36 | -1.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.